TACSTD2 and breast carcinoma: However, advances in breast cancer research such as the development of new chemotherapeutics and endocrine or targeted therapies as well as PDL1-, TROP-2, PARP-, and CDK4/6-inhibitors have rendered multiple new and well-tolerated treatment options demonstrating survival benefits in high-risk breast cancer patients.